FDA-approved Hormones & metabolism

Pramlintide

Pramlintide is an amylin analog. It is filed in this library under hormones & metabolism, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Pramlintide has an FDA-approved product on the U.S. market, marketed as Symlinpen under application NDA021332.

The current label is held by AstraZeneca Pharmaceuticals LP.

From the FDA label

What Pramlintide is approved to treat

is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy.Quoted from the FDA-approved prescribing information

Boxed warning

The most serious warning on its label

WARNING: SEVERE HYPOGLYCEMIA SYMLIN use with insulin increases the risk of severe hypoglycemia, particularly in patients with type 1 diabetes. When severe hypoglycemia occurs, it is seen within 3 hours following a SYMLIN injection. Serious injuries may occur if severe hypoglycemia occurs while operating a motor vehicle, heavy machinery, or while engaging in other high-risk activities. Appropriate patient selection, careful patient instruction, and insulin dose reduction are critical elements for reducing this risk. WARNING: SEVERE HYPOGLYCEMIA See full prescribing information for complete boxed warning. • SYMLIN use with insulin has been associated with an increased risk of severe hypoglycemQuoted from the FDA-approved prescribing information

The evidence

What has actually been published

We could not resolve a published study for Pramlintide to a verifiable source. That absence is itself worth knowing, and we would rather say so than fill the space.

Nearby

Other peptides acting on hormones & metabolism

Markers on this pathway

What is measured when blood sugar and insulin is assessed

Pramlintide's FDA-approved label indicates it for glycemic control or for a glucose emergency. These are the markers clinicians use when assessing blood sugar and insulin. They are listed here so you can read about them, not as a statement that Pramlintide changes any of them.

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Pramlintide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides